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Abstract
Background. Sleep disorders in kidney disease patients occur more frequently than in the general population. 
Chronic renal disease patients are commonly diagnosed with sleep apnoea syndrome. It occurs in the obstructive, 
central and mixed form and is of multicausal nature. The aim of the present paper was to assess the frequency of 
individual types of sleep-related breathing disorders in chronically haemodialysed patients using polysomnography. 
Material and methods. The study involved stage 5 CKD patients receiving continuous renal replacement therapy 
by haemodialysis. 
Results. The obtained results suggest that weight gain between consecutive haemodialysis sessions correlates with 
more frequent occurrences of disordered breathing events (apnoeas and hypopnoeas) in patients on the night preced-
ing haemodialysis session. 
Conclusions. Positive linear correlations are observed of systolic and diastolic BP measured before PSG performed 
on the day before a haemodialysis session with the number of snoring episodes, which might suggest that breathing 
disorders affect the complex pathogenesis of hypertension in haemodialysed patients.
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Introduction
Sleep constitutes a very important part of human life. 
It usually takes up a fourth, and in some cases even 
a third of a person’s life. Sleep requirements vary be-
tween individuals. Research studies suggest that sleep 
deprivation, i.e. sleeping less than 6 hours a night, 
or excessive sleep, i.e. sleeping more than 9 hours 
a night, correlates with an increased risk of prema-
ture death. Many researchers have stressed the signif-
icance of sleep in human life. It is needed to restore 
the efficiency of the organism, allows economising 
on limited energy resources and provides protec-
tion against excessive stress [1–4]. During sleep, the 
supply of energy-rich phosphates becomes restored, 
the synthesis of proteins and neurotransmitters im-
proves, and cell division processes accelerate [3, 4].
Sleep disorders in patients with kidney disease 
are more frequent than in the general population. 
Merlino et al. observed the occurrence of such disor-
ders in about 80% out of 883 investigated patients 
receiving haemodialysis (HD) treatment. The most 
common types of sleep disorders were: insomnia 
(69% of patients), restless legs syndrome (18%), 
obstructive sleep apnoea syndrome (24%), and ex-
cessive daytime sleepiness (12%) [5]. From among 
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the above conditions, the sleep apnoea syndrome is 
relatively often diagnosed in patients with chronic 
kidney disease (CKD). It occurs in the obstructive, 
central and mixed form and is of multicausal nature.
Comparing the frequency of occurrence of three 
main types of sleep-related breathing disorders, that 
is the obstructive, central and mixed forms of ap-
noea, stage 5 CKD patients are most often diagnosed 
with central, and only slightly less frequently with 
the obstructive form of apnoea [15].
Sabatini et al. confirmed the increased prevalence 
of sleep disorders in haemodialysed patients [16]. 
The finding applied to patients receiving dialysis 
treatment in the mornings for over 12 months and 
with increased PTH levels. Disorders observed most 
frequently were: frequent nighttime awakenings 
(92% of cases), difficulty falling asleep (67%), and 
early-morning awakenings (62%).
The most significant of the consequences of 
sleep-related breathing disorders are cardiovascular 
complications. Conditions occurring more frequent-
ly in this group of patients are: resistant hyperten-
sion, left ventricular hypertrophy, ischaemic heart 
disease, and malignant arrhythmia. Higher preva-
lence of myocardial infarction and stroke has also 
been observed [17–19]. Extreme cases of sleep dis-
orders — excessive daytime sleepiness — lead to an 
increased number of traffic accidents, which in turn 
contributes to a further increase in mortality rates. 
There have been numerous explanations for the in-
creased prevalence of sleep-related breathing disorders 
in patients receiving continuous haemodialysis ther-
apy. Significance has been attached to the co-occur-
rence of atherosclerosis and diabetes, and partly to the 
presence of such risk factors as the age of over 40 years, 
male gender, obesity, or arterial hypertension [21]. 
There are several hypotheses partially explaining the 
causes of the increased frequency of occurrence of such 
disorders in patients with end-stage renal disease. One 
of those has been believed to be metabolic acidosis. 
However, studies carried out by Kimmel et al. did not 
find any correlations between metabolic acidosis and 
apnoea episodes in haemodialysed patients [7, 22].
The significance of anaemia has been considered 
as another hypothetical factor contributing to the 
development of sleep apnoea in patients on dialysis. 
However, research studies conducted by Benz et al. 
demonstrated that anaemia correction had no impact 
on the number of apnoeas during sleep [23, 24].
Another causal factor taken into account is the sig-
nificance of uremic neuropathy and myopathy and 
the consequent disturbed functioning of respiration 
muscles [21]. Disorders in neuromuscular transmis-
sion caused by uremic toxins aggravate breathing 
disorders. In the case of effective HD treatment, 
the clinical symptoms of uremic neuropathy rarely 
occur, although its subclinical manifestation can be 
diagnosed in 50% of cases. This hypothesis might 
be supported by the fact that a regression of clinical 
symptoms of uremic neuropathy and a decrease in 
the number and severity of apnoeas are observed in 
post-kidney transplant patients [25–27].
Aim of the study
The aim of the present study was to analyse the fre-
quency of occurrence of different types of sleep-related 
breathing disorders in patients receiving continuous 
haemodialysis therapy. The assessment was based on 
polysomnographic tests performed before and directly 
after haemodialysis sessions in conjunction with the 
analysis of biochemical, anthropometric and blood pres-
sure data, as well as their correlations with the frequency 
of occurrence of breathing disorders during sleep.
Material and methods
The research study was conducted under permission 
granted by the Bioethics Committee in the Labora-
tory of Chronobiology and Chronomedicine of the 
Department of Human Physiology and the Depart-
ment of Epidemiology of the Nicolaus Copernicus 
University Collegium Medicum in Bydgoszcz. 
The study involved patients with stage 5 CKD, 
receiving continuous renal replacement therapy by 
haemodialysis in the Dialysis Centre of the Clinic of 
Nephrology, Hypertension and Internal Diseases of 
the University Hospital No. 1 in Bydgoszcz. 
The study was carried out in three stages. The first 
stage consisted in a survey study using the Epworth 
Sleepiness Scale aimed at identifying patients with the 
highest risk for sleep-related breathing disorders. The 
first-stage assessment included 61 patients (24 women 
and 37 men) aged 28 to 78 (mean age 58.2 ± 12.2) with 
mean dry weight of 68.16 ± 13.57 kg, receiving dialysis 
three times a week for an average of 73.49 ± 55.33 
months. The mean duration of an HD session was 
4.43 ± 0.43 hours. The second and third stage of the 
study involved full polysomnography (PSG) performed 
on the night directly before and after an HD session 
using the Alice 3 Diagnostic Sleep System by Respi-
ronics. This stage included 17 men, receiving dialysis 
between 7.00 p.m. and 11.00 p.m. A follow-up PSG 
test was eventually performed in 11 patients. 6 patients 
were excluded from the third stage of the study due to: 
kidney transplantation (1 patient), death (3 patients), 
withheld consent for a follow-up PSG test (2 patients). 
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Table I. Clinical characteristics of patients
Parameters Clinical characteristics of patients
Age BMI HD session 
duration
HD duration 
(months)
Dry weight Weight gain 
between HD
Hours of sleep
Min 28 15.00 3.50 7.00 38.00 1.00 2.00
Max 78 36.00 5.50 236.00 98.50 4.30 10.00
Median 58.0 24.00 4.50 58.00 66.00 2.50 6.25
Mean 58.2 23.77 4.43 73.49 68.16 2.46 6.46
SD 12.2 4.11 0.43 55.53 13.57 0.70 2.05
Table II. Values of breathing parameters recorded during sleep in patients receiving continuous haemodialysis therapy
Total number of 
apnoeas
Number of central 
apnoeas
Number of 
obstructive 
apnoeas
Number of mixed 
apnoeas
Number of 
hypopnoeas
Number of snoring 
episodes
After
HD
Btwn 
HDs
After
HD
Btwn 
HDs
After
HD
Btwn 
HDs
After
HD
Btwn 
HDs
After
HD
Btwn 
HDs
After
HD
Btwn 
HDs
n 17 11 17 11 17 11 17 11 17 11 17 11
Min 1 2 0 0 0 0 0 0 1 1 0 0
Max 142 354 127 119 110 194 29 41 79 172 255 284
Median 37.0 43.0 21.0 13.0 5.0 13.0 2.0 1.0 34.0 63.0 20.0 52.0
Mean 56.9 68.6 27.7 27.7 19.1 33.0 4.2 7.9 31.6 62.1 37.3 77.7
SD 45.9 102.2 31.9 39.5 29.0 55.7 7.3 12.7 23.3 54.6 60.3 94.5
Table III. Index of breathing events per one hour of recorded sleep
Index of breathing 
events per 1 hour of 
sleep
Index of central 
apnoeas per 1 hour of 
sleep
Index of obstructive 
apnoeas per 1 hour of 
sleep
Index of mixed 
apnoeas per 1 hour of 
sleep
Index of hypopnoeas 
per 1 hour of sleep
After
HD
Btwn HDs After
HD
Btwn HDs After
HD
Btwn HDs After
HD
Btwn HDs After
HD
Btwn HDs
n 17 11 17 11 17 11 17 11 17 11
Min 0.9 0.9 0 0 0 0 0 0 0.1 0.1
Max 35.2 45.4 22.1 15 18.8 16.8 5.4 3.5 15 17.3
Median 15.6 17.1 4.5 2.1 1.9 1.7 0.3 0.2 7.7 10.4
Mean 17.9 17.4 5.9 3.9 3.8 3.9 1.1 1.0 7.0 8.6
SD 12.0 14.0 6.0 4.8 5.1 5.0 1.8 1.4 4.6 6.0
Table I presents the clinical characteristics of patients 
participating in the study — qualified for the first stage.
Results
Table II presents the values of breathing parameters 
recorded during sleep in patients receiving continu-
ous haemodialysis. During the performed polysom-
nography, the highest number of breathing events 
was observed between HDs — a total of 208.4 
breathing events was observed, including a total of 
68.6 ± 102.2 apnoeas (including: 27.7 ± 39.5 central 
apnoeas, 33 ± 55.7 obstructive apnoeas, and 7.9 ± 
12.7 mixed apnoeas), 62.1 ± 54.6 hypopnoeas, and 
77.7 ± 94.5 snoring episodes.
Table III presents the index of breathing events 
recorded during sleep.
Statistically significant linear correlations were 
found between BMI and the number of central ap-
noeas in the group of patients examined between 
HD sessions (btwn HDs), and between BMI and 
the number of central apnoeas in the group of 
patients after HD sessions (after HD) (Table IV).
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Table IV. Values of linear correlation coefficients between BMI and the number of central and mixed apnoeas
n Btwn HDs After HD
R
Spearman
p R
Spearman
p
BMI & total number of apnoeas 10 0.64 0.0479 0.53 0.1173
BMI & total number of hypopnoeas 10 0.43 0.2202 0.52 0.1276
BMI & number of central apnoeas 10 0.59 0.0717 0.83 0.0029
BMI & number of obstructive apnoeas 10 0.30 0.4032 0.10 0.7770
BMI & number of mixed apnoeas 10 0.56 0.0948 0.66 0.0360
BMI & number of snoring episodes 10 –0.05 0.8810 0.16 0.6515
BMI & systolic BP 10 –0.17 0.6372 0.04 0.9059
BMI & diastolic BP 10 –0.21 0.5541 –0.02 0.9587
Table V. Linear correlations between body weight gain and the number of breathing events
n R Spearman p-value
Δ body weight btwn HDs & total number of apnoeas btwn HDs 10 0.60 0.0667
Δ body weight btwn HDs & total number of hypopnoeas btwn HDs 10 0.57 0.0844
Δ body weight btwn HDs & number of central apnoeas btwn HDs 10 0.56 0.0916
Δ body weight btwn HDs & number of obstructive apnoeas btwn HDs 10 0.30 0.3932
Δ body weight btwn HDs & number of mixed apnoeas btwn HDs 10 0.56 0.0948
Δ body weight btwn HDs & number of snoring episodes btwn HDs 10 0.27 0.4458
Positive correlations were found between body 
weight gain (∆ body weight) between HDs and the 
total number of apnoeas between HDs, and between 
body weight gain (∆ body weight) and the number of 
mixed apnoeas and hypopnoeas (Table V).
Positive linear correlations were found between 
systolic and diastolic BP measured before PSG per-
formed on the day prior to the next HD session and 
the number of snoring episodes.
Discussion
Sleep-related breathing disorders constitute a ma-
jor clinical problem in the general population and in 
the population of patients with CKD receiving both 
conservative and renal replacement treatment.
In Poland, there is still no epidemiological data on 
the matter. There has not yet been any detailed ex-
planation of the causes responsible for the increased 
prevalence of sleep apnoea syndromes in patients suf-
fering from kidney diseases. One of the many factors 
considered to play a significant role in the occurrence 
of sleep apnoea in the said population of patients is 
the effect of uremic toxins, metabolic acidosis and 
overhydration on the mechanisms of breathing re-
gulation. The impact of anaemia on the increased 
frequency of sleep apnoea has also been taken into 
account; however, it has been demonstrated that im-
proving the levels of haemoglobin and haematocrit 
has no significant effect on decreasing the number of 
apnoeas during sleep in patients treated with conti-
nuous haemodialysis [8, 23, 24, 28]. A decisive role 
in identifying the sleep apnoea syndrome is played 
by polysomnography. It allows determining the fre-
quency of occurrence and type of breathing disorders 
with the greatest accuracy. According to the results 
of recent studies, the prevalence of sleep apnoea syn-
dromes in CKD patients is ten times higher than in 
the general population. Over 50% (53–75% as re-
ported by different sources) of patients are diagnosed 
with sleep-related breathing disorders [6–8, 29] and 
approximately 54–80% of patients suffer from at 
least one type of sleep disorder. It has also been found 
that the frequency of occurrence of sleep apnoea is 
similar between the group of CKD patients receiv-
ing conservative treatment and the group of patients 
receiving renal replacement therapy [29, 30]. The 
type of dialysis treatment (peritoneal dialysis vs hae-
modialysis) is of no real significance in reducing the 
number of apnoeas during sleep [8]. Changing the 
form of treatment from conventional haemodialysis 
(intermittent HD sessions) to nocturnal haemodia-
lysis administered for 6–7 nights a week decreases the 
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frequency and severity of sleep apnoeas and improves 
the quality of life of patients [31, 32]. 
PSG tests performed in the present study deter-
mined a quantitative prevalence of central apnoeas 
over obstructive ones, although the difference was 
of no statistical significance. Similar findings were 
reported by Kimmel et al. [7]. In a study by Yeh 
et al., 62% of patients had mixed apnoea, while 
the remaining 38% had obstructive apnoea [42]. In 
a study by Rodriguez et al., 31.1% out of 45 exa-
mined patients had AHI ≥ 5; the obstructive type 
of apnoea was prevalent in those patients [43]. In 
patients with CKD, central and obstructive apnoeas 
are mainly observed.
In the present study, an attempt was made to 
assess the effect of an HD session on the frequency 
of occurrence of breathing disorders. The number of 
disordered breathing events was higher on the night 
before an HD session, although no statistical sig-
nificance was determined. A statistically significant 
lower number of hypopnoeas was observed during 
PSG performed directly after an HD session.
Moreover, positive correlations were found be-
tween body weight gain (∆ weight) between HDs 
and the total number of apnoeas between HDs, 
and between body weight gain (∆ weight) and 
the number of mixed apnoeas and hypopnoeas 
between HDs.
Although the present study found no statistical-
ly significant difference between the aggravation 
of metabolic acidosis and the frequency of disor-
dered breathing events, a decrease in the number 
of hypopnoeas observed in PSG tests after HD 
sessions suggests that controlling metabolic acidosis 
and electrolyte imbalance, as well as reducing the 
concentration of uremic toxins in plasma, might 
exert a positive effect on decreasing the number 
of disordered breathing events. The occurrence of 
an increased number of central apnoeas during 
PSG between HDs indicates a possible depres-
sive effect of such biochemical factors as metabolic 
acidosis and uremic toxins on the respiratory 
centre. Nevertheless, no correlations were found 
between acidosis and the number of disordered 
breathing events. It may thus be only tentatively 
concluded that a haemodialysis session has a posi-
tive impact on the improvement of breathing disor-
ders during sleep in patients receiving continuous 
haemodialysis treatment. Due to the too limited 
size of the study group and the diverse pathophys-
iological mechanism of sleep apnoea in patients 
suffering from chronic renal disease, it is difficult 
to assess the true impact of HD treatments on the 
sleep apnoea syndrome.
Arterial hypertension is a significant risk factor 
for cardiovascular complications in haemodialysed 
patients [46]. Epidemiological studies have indicated 
that patients with obstructive sleep apnoea have in-
creased arterial blood pressure [47–50]. This applies 
to both the general population and the population of 
kidney disease patients.
Sleep apnoeas lead to an increase in systolic and 
diastolic blood pressure by about 25–30% [4]. It 
is caused by the increased activation of chemore-
ceptors in response to the developing hypoxaemia 
and hypercapnia [4, 52]. Furthermore, a significant 
role in the development of hypertension in sleep 
apnoea patients is played by a decreased reactivity 
of arterial baroreceptors, an increased activity of the 
sympathetic nervous system, the effect of hormonal 
factors (catecholamines), and the stimulation of the 
renin-angiotensin-aldosterone system [51, 52]. In 
the present study, positive linear correlations were 
found between the values of systolic and diastolic BP 
measured before PSG performed on the day prior to 
the next haemodialysis session and the number of 
snoring episodes. The observed finding might have 
been caused by the aggravating symptoms of overhy-
dration with concurrent metabolic disorders leading 
to the obstruction of the upper airway — an oedem-
atous component within the nasopharynx. What is 
more, the increased frequency of central apnoeas 
was most likely caused by metabolic disorders in-
tensifying due to the interval between haemodialysis 
sessions. The observations on arterial hypertension 
made in the present study confirm the findings of 
Rodriguez et al. [43], whereas Kuhlman et al. found 
no statistically significant differences in arterial hy-
pertension between patients with and without sleep 
apnoea [28]. The discrepancies in results might be 
due to the inhomogeneity of study groups. It is dif-
ficult to determine the exact nature of arterial hy-
pertension in patients suffering from sleep apnoea. 
Davies et al. determined an increase in systolic pres-
sure and a slight decrease in diastolic pressure at 
night compared to measurements taken during the 
day [52]. In studies carried out by Grote et al., the 
most common type of hypertension in sleep apnoea 
patients was systolic-diastolic hypertension.
Additional comments
The values of the obtained results might have been 
affected by the too limited size of the study group 
resulting from the unwillingness of patients to parti-
cipate in polysomnography tests. The same issue has 
been addressed by other authors working on similar 
research problems. The majority of patients who par-
ticipated in the first stage of the present study, i.e. in 
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the questionnaire survey, withdrew from participat-
ing in the further stage upon being instructed in the 
course of the examination. For this reason, 17 men 
went on to take part in the second stage and only 11 
in the third stage of the study.
Conclusions
On the basis of the results of the present study it might 
be concluded that body weight gain between haemo-
dialysis sessions correlated with an increased number 
of disordered breathing events (apnoeas and hypop-
noeas) observed in patients during the night before 
an HD session. Moreover, positive linear correlations 
have been observed between the values of systolic and 
diastolic BP measured before PSG performed on the 
day before the next HD session and the number of 
snoring episodes, which might suggest a possible effect 
of breathing disorders on the complex pathogenesis of 
arterial hypertension in haemodialysed patients.
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